We would love to hear your thoughts about our site and services, please take our survey here.
Does anyone think that any deal may hinge on patents being approved prior to transaction? If so this is a good sign.
LOL!!! Well done Soup.
Https://www.nytimes.com/2023/05/21/business/economy/minerals-electric-cars-batteries.html
I jumped back in at 1.25 several weeks back with a small amount and added more today. Not bank breaking amounts but a little could do a lot at this low valuation and with the NXP 002 an odds on for good data its certainly worth a small punt for potential life changing results. Could take a while for the deals to develop but I am hoping for some good murmurs by the end of the year so this can lift itself out of the doldrums. NXP 004 could add some momentum as and when we learn more.
From Their RNS today - Interesting they have selected 2 LFT's to provide -
Excalibur Healthcare Services LF Antigen for Professional Use & Everything Genetic Limited for both Professional & Home Use. The Excalibur LFT claims 100% sensitivity & specificity for " for high viral loads (equivalent to positive PCR values below Ct=28)":
"The Group's COVID-19 RT PCR testing throughput has progressively increased since the first half of the year, with average daily testing volumes in July approaching 7,000 which is more than double the rate in the first half, average testing in August exceeding 10,000 per day and average testing in September to date at approximately 14,000 per day.
A significant proportion of the Group's PCR testing volumes and revenues are currently derived from Day 2, Day 8 and "Fit to Fly" testing. Day 2 and Day 8 testing will be removed under the new travel rules from the end of October for fully vaccinated individuals and low-risk countries. The requirements surrounding PCR testing for out-bound travel, the "Fit to Fly" scheme, and D2 and D8 from red list countries do not appear to be impacted and the Board expects that these newly announced changes to international travel will likely encourage more people to travel abroad from the UK, and that this should contribute to a rise in "Fit to Fly" out-bound testing volumes.
The Group anticipates that a material proportion of travel related demand will switch from PCR technology to lateral flow technology. SourceBio has evaluated a number of lateral flow technologies and has signed two commercial distribution agreements for the ongoing supply of lateral flow tests. The first agreement is with Excalibur Healthcare Services Limited for the supply of their new Lateral Flow Test, the Excalibur Rapid SARS-COV-2 Antigen Test. This test kit is approved for professional use in Europe and the UK, and has demonstrated close to 100% specificity and 100% sensitivity for high viral loads (equivalent to positive PCR values below Ct=28). The Excalibur test kit may also be combined with a "Test to go" scanning app and Travel Pack that has been proven to provide a more accurate reading of results than the human eye. The second agreement is with Everything Genetic Limited which also offers a home use option for lateral flow antigen testing."
Google gave me the shock of a lifetime... currently showing SO4 up 9,200%... if only!
Back down to placing prices again... who would have thought. Hard not to put a bit more in at these levels but then again...
Well done huff post for a well written and compelling article. Thanks for sharing...
https://www.huffingtonpost.co.uk/entry/pm-under-fire-for-empty-promises-made-to-uk-biotech-firms-over-covid-tests_uk_60e553f5e4b099d899a1d4da
Feels like we will get there eventually. Going to be very hard for BOJO and the gang to continue to completely ignore us without increasing political backlash...
Anybody dial in Today? I was in a lunch meeting unfortunately.
After watching this daily since I exited back in Oct 19 (circa 10p) I have dipped my toe back in with a few K. The Mcap is so low against all the potential products in the pipeline - still tightly held - the tech being used on existing drugs - makes approvals very low risk - small expenditure - placing dilution very minor in comparison to some other shares... This could easily do a few bags on minor news and 10 to 20 bags easy on great news (NXP2 rights to????) Worth having a bit of punt money in just to wait and see.
Once they get their leadership restructure sorted the could fly. Happy to be in with some bottom drawer funds at a low price so I can check in once a week rather than twice a day and let it ride.
Quite an interesting story in the NYT today on the path to development for the Phizer and Moderna vaccines, amazing the actually had the designs within days / weeks with the trials obviously taking the bulk of the time to navigate. Gives some really good insight into the extents of potential political tampering that these companies had to navigate....
Politics, Science and the Remarkable Race for a Coronavirus Vaccine
https://nyti.ms/3pTBVfE
Look at CKs cv and Omega's history. Distribution is our bread and butter. This should be where we shine. Let's see where we can get to with capacity!
https://www.nytimes.com/2020/09/06/health/coronavirus-rapid-test.html
Main argument is that poc antigens are unreliable and that quantity over quality may still be beneficial. What if you could have both?
My my... 14 out of 18 of the last posts show as a lovely shade of green... wonder who they could be??? Actually I dont. Great to see the Ulster testing info through today. Good times to come. Resilience is key, for our investment and the country.
Coronavirus News: Strong Immunity May Follow Even Mild Cases
https://nyti.ms/3askw6p
Been watching the trades since the rise yesterday, strange small trades going through, some single digits, lots below 100, a few between 100-200, all buys, any ideas? These certainly wouldn't be worth the trading fees so assuming not PIs...
Also in the NY Times
COVID-19 Antibody Test Passes First Major Trials in UK With 98.6% Accuracy
https://nyti.ms/3fFU3nD
Great Exposure
ht tps://www.**********.co.uk/articles/omega-diagnostics-pivots-to-rapid-development-of-covid-19-tests--5d09af5
The FinnCap report is definitely worth a read. Can be accessed for free through their website if you register.
hTTps://researchlibrary.finncap.com/
Has a whole section on potential valuation of the company based on increased capacity and potential full rates.
hTTps://www.forbes.com/sites/csylt/2020/04/14/how-f1-could-make-530-million-of-revenue-from-eight-races/#3b7201cd355f
Apr 14, 2020,02:20pm EDT
How F1 Could Make $530 Million Of Revenue From Eight Races
'F1, perhaps more than any other sport, has been dented by the coronavirus as its races attract huge crowds and take place in more than 20 countries over an eight-month period. In order for F1 to create a calendar, not only must borders be open but mass gatherings must be allowed in all of its race locations.
These hurdles have sent F1’s stock price into reverse and it has lost 47.6% of its value since the start of the year.'